These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

238 related items for PubMed ID: 34091209

  • 1. Design, synthesis, and biological evaluation of 2,4-diamino pyrimidine derivatives as potent FAK inhibitors with anti-cancer and anti-angiogenesis activities.
    Wang S, Zhang RH, Zhang H, Wang YC, Yang D, Zhao YL, Yan GY, Xu GB, Guan HY, Zhou YH, Cui DB, Liu T, Li YJ, Liao SG, Zhou M.
    Eur J Med Chem; 2021 Oct 15; 222():113573. PubMed ID: 34091209
    [Abstract] [Full Text] [Related]

  • 2. Discovery of 2,4-diarylaminopyrimidine derivatives bearing dithiocarbamate moiety as novel FAK inhibitors with antitumor and anti-angiogenesis activities.
    Su Y, Li R, Ning X, Lin Z, Zhao X, Zhou J, Liu J, Jin Y, Yin Y.
    Eur J Med Chem; 2019 Sep 01; 177():32-46. PubMed ID: 31129452
    [Abstract] [Full Text] [Related]

  • 3. Design, synthesis, biological evaluation and molecular docking study of novel thieno[3,2-d]pyrimidine derivatives as potent FAK inhibitors.
    Wang R, Yu S, Zhao X, Chen Y, Yang B, Wu T, Hao C, Zhao D, Cheng M.
    Eur J Med Chem; 2020 Feb 15; 188():112024. PubMed ID: 31923858
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. New thieno[3,2-d]pyrimidine-based derivatives: Design, synthesis and biological evaluation as antiproliferative agents, EGFR and ARO inhibitors inducing apoptosis in breast cancer cells.
    Farghaly AM, AboulWafa OM, Baghdadi HH, Abd El Razik HA, Sedra SMY, Shamaa MM.
    Bioorg Chem; 2021 Oct 15; 115():105208. PubMed ID: 34365057
    [Abstract] [Full Text] [Related]

  • 6. Design, synthesis and biological evaluation of ring-fused pyrazoloamino pyridine/pyrimidine derivatives as potential FAK inhibitors.
    Xie H, Lin X, Zhang Y, Tan F, Chi B, Peng Z, Dong W, An D.
    Bioorg Med Chem Lett; 2020 Nov 01; 30(21):127459. PubMed ID: 32784087
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Design, synthesis, and biological evaluation of novel covalent inhibitors targeting focal adhesion kinase.
    Chen T, Liu Y, Shi M, Tang M, Si W, Yuan X, Wen Y, Chen L.
    Bioorg Med Chem Lett; 2021 Dec 15; 54():128433. PubMed ID: 34757216
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Design, synthesis and antitumor evaluation of novel 5-methylpyrazolo[1,5-a]pyrimidine derivatives as potential c-Met inhibitors.
    Luo G, Ma Y, Liang X, Xie G, Luo Y, Zha D, Wang S, Yu L, Zheng X, Wu W, Zhang C.
    Bioorg Chem; 2020 Nov 15; 104():104356. PubMed ID: 33142417
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Design and synthesis of thienopyrimidine urea derivatives with potential cytotoxic and pro-apoptotic activity against breast cancer cell line MCF-7.
    Abdelhaleem EF, Abdelhameid MK, Kassab AE, Kandeel MM.
    Eur J Med Chem; 2018 Jan 01; 143():1807-1825. PubMed ID: 29133058
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Design, synthesis, and biological evaluation of 2,6,7-substituted pyrrolo[2,3-d]pyrimidines as cyclin dependent kinase inhibitor in pancreatic cancer cells.
    Shi X, Quan Y, Wang Y, Wang Y, Li Y.
    Bioorg Med Chem Lett; 2021 Feb 01; 33():127725. PubMed ID: 33316409
    [Abstract] [Full Text] [Related]

  • 18. A first-in-class anticancer dual HDAC2/FAK inhibitors bearing hydroxamates/benzamides capped by pyridinyl-1,2,4-triazoles.
    Mustafa M, Abd El-Hafeez AA, Abdelhamid D, Katkar GD, Mostafa YA, Ghosh P, Hayallah AM, Abuo-Rahma GEA.
    Eur J Med Chem; 2021 Oct 15; 222():113569. PubMed ID: 34111829
    [Abstract] [Full Text] [Related]

  • 19. Pyrazolo[3,4-d]pyrimidine-based dual EGFR T790M/HER2 inhibitors: Design, synthesis, structure-activity relationship and biological activity as potential antitumor and anticonvulsant agents.
    Lamie PF, El-Kalaawy AM, Abdel Latif NS, Rashed LA, Philoppes JN.
    Eur J Med Chem; 2021 Mar 15; 214():113222. PubMed ID: 33545637
    [Abstract] [Full Text] [Related]

  • 20. Discovery and preclinical evaluation of 7-benzyl-N-(substituted)-pyrrolo[3,2-d]pyrimidin-4-amines as single agents with microtubule targeting effects along with triple-acting angiokinase inhibition as antitumor agents.
    Pavana RK, Choudhary S, Bastian A, Ihnat MA, Bai R, Hamel E, Gangjee A.
    Bioorg Med Chem; 2017 Jan 15; 25(2):545-556. PubMed ID: 27894589
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.